Leflunomide as adjuvant treatment of dermatomyositis J. Scott Boswell, MD, Melissa I. Costner, MD Journal of the American Academy of Dermatology Volume 58, Issue 3, Pages 403-406 (March 2008) DOI: 10.1016/j.jaad.2007.08.014 Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 A, Face and B, hands of patient 1 before treatment with leflunomide. Journal of the American Academy of Dermatology 2008 58, 403-406DOI: (10.1016/j.jaad.2007.08.014) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 A, Face and B, hands of patient 1 after 1 year of treatment with leflunomide. Journal of the American Academy of Dermatology 2008 58, 403-406DOI: (10.1016/j.jaad.2007.08.014) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 Timeline of systemic therapy for patients 1 to 3. AZA, Azathioprine; bid, twice a day; DM, dermatomyositis; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; PRED, prednisone; qd, 4 times a day; qw, q week; QUIN, quinacrine. Journal of the American Academy of Dermatology 2008 58, 403-406DOI: (10.1016/j.jaad.2007.08.014) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions